Compare
Alzamend Neuro, Inc. vs Inhibitor Therapeutics, Inc. vs Artelo Biosciences, Inc. vs BullFrog AI Holdings, Inc.
| Latest fiscal year | Alzamend Neuro, Inc. ALZN | Inhibitor Therapeutics, Inc. INTI | Artelo Biosciences, Inc. ARTL | BullFrog AI Holdings, Inc. BFRG |
|---|---|---|---|---|
| Year ended | 2026-04-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $116.7K |
| Revenue growth (YoY) | n/a | n/a | n/a | n/a |
| Gross margin | n/a | n/a | n/a | 18.8% |
| Operating margin | n/a | n/a | n/a | n/m |
| Net margin | n/a | n/a | n/a | n/m |
| Net income | -$8.77M | -$3.30M | -$12.88M | -$6.50M |
| EPS (Diluted) | -$2.63 | -$0.02 | -$12.52 | -$0.63 |
| Operating cash flow | -$8.07M | -$3.23M | -$8.52M | -$5.52M |
| Free cash flow | n/a | n/a | n/a | n/a |
| Cash & equivalents | $710.7K | $2.38M | $600.0K | $2.18M |
| Total assets | $2.08M | $2.51M | $2.80M | $2.81M |
| Total liabilities | $1.35M | $3.80M | $4.07M | $672.0K |
| Shareholders' equity | $733.2K | -$1.29M | -$1.27M | $2.14M |
| Return on year-end equity | n/m | n/a | n/a | -304.2% |
| Shares outstanding | 4.26M | 172.57M | 2.02M | 11.42M |
Revenue, most recent five fiscal years
| Fiscal year | Alzamend Neuro, Inc. | Inhibitor Therapeutics, Inc. | Artelo Biosciences, Inc. | BullFrog AI Holdings, Inc. |
|---|---|---|---|---|
| Latest | n/a | $0 Ended 2021-12-31 | n/a | $116.7K Ended 2025-12-31 |
| 1 year earlier | n/a | $0 Ended 2020-12-31 | n/a | n/a |
| 2 years earlier | n/a | $0 Ended 2019-12-31 | n/a | $65.0K Ended 2023-12-31 |
| 3 years earlier | n/a | $0 Ended 2018-12-31 | n/a | $10.0K Ended 2022-12-31 |
| 4 years earlier | n/a | $0 Ended 2017-12-31 | n/a | n/a |